435 related articles for article (PubMed ID: 32653075)
1. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
van Zyl-Smit RN; Krüll M; Gessner C; Gon Y; Noga O; Richard A; de Los Reyes A; Shu X; Pethe A; Tanase AM; D'Andrea P;
Lancet Respir Med; 2020 Oct; 8(10):987-999. PubMed ID: 32653075
[TBL] [Abstract][Full Text] [Related]
2. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Kerstjens HAM; Maspero J; Chapman KR; van Zyl-Smit RN; Hosoe M; Tanase AM; Lavecchia C; Pethe A; Shu X; D'Andrea P;
Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
[TBL] [Abstract][Full Text] [Related]
3. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
Gessner C; Kornmann O; Maspero J; van Zyl-Smit R; Krüll M; Salina A; Gupta P; Bostel S; Fucile S; Conde LG; Pfister P
Respir Med; 2020; 170():106021. PubMed ID: 32843164
[TBL] [Abstract][Full Text] [Related]
4. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
Beeh KM; Kirsten AM; Tanase AM; Richard A; Cao W; Hederer B; Beier J; Kornmann O; van Zyl-Smit RN
Int J Chron Obstruct Pulmon Dis; 2018; 13():3923-3936. PubMed ID: 30584293
[TBL] [Abstract][Full Text] [Related]
5. Once-daily, single-inhaler indacaterol/mometasone versus twice-daily salmeterol/fluticasone in Asian patients with inadequately controlled asthma:
Gon Y; Ishii T; Lawrence D; Nikolaev I; Wang D; Sumi K; Nakamura Y
J Asthma; 2022 Aug; 59(8):1627-1637. PubMed ID: 34346266
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings.
Kornmann O; Mucsi J; Kolosa N; Bandelli L; Sen B; Satlin LC; D'Andrea P
Respir Med; 2020 Jan; 161():105809. PubMed ID: 32056721
[TBL] [Abstract][Full Text] [Related]
7. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
Watz H; Hohlfeld JM; Singh D; Beier J; Diamant Z; Liu J; Hua S; Abd-Elaziz K; Pinot P; Jones I; Tillmann HC
Respir Res; 2020 Apr; 21(1):87. PubMed ID: 32295593
[TBL] [Abstract][Full Text] [Related]
8. One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies.
Chapman K; van Zyl-Smit R; Maspero J; Kerstjens HAM; Gon Y; Hosoe M; Tanase AM; Pethe A; Shu X; D'Andrea P
BMJ Open Respir Res; 2021 Aug; 8(1):. PubMed ID: 34452934
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.
Buhl R; Tanase AM; Hosoe M; Cao W; Demin I; Bartels C; Jauernig J; Ziegler D; Patalano F; Hederer B; Kanniess F; Tillmann HC
Pulm Pharmacol Ther; 2020 Jun; 62():101919. PubMed ID: 32387408
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population.
Sagara H; Barbier N; Ishii T; Yoshisue H; Nikolaev I; Hosoe M; Gon Y
BMJ Open Respir Res; 2021 Mar; 8(1):. PubMed ID: 33737310
[TBL] [Abstract][Full Text] [Related]
11. A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
Brittain D; D'Andrea P; Gruen E; Hosoe M; Jain D; Jauernig J; Pethe A; Scosyrev E; Tanase AM; Tillmann HC
Adv Ther; 2022 Jun; 39(6):2365-2378. PubMed ID: 35072888
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.
Scosyrev E; van Zyl-Smit R; Kerstjens H; Gessner C; Kornmann O; Jain D; Aubrun E; D'Andrea P; Hosoe M; Pethe A; Brittain D
Respir Med; 2021; 180():106311. PubMed ID: 33711782
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
Van Zyl-Smit RN; Kerstjens HA; Maspero JF; Kostikas K; Hosoe M; Tanase AM; D'Andrea P; Mezzi K; Brittain D; Lawrence D; Chapman KR
Respir Med; 2023 May; 211():107172. PubMed ID: 36906187
[TBL] [Abstract][Full Text] [Related]
14. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
Bernstein D; Andersen L; Forth R; Jacques L; Yates L
J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
[TBL] [Abstract][Full Text] [Related]
16. Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma.
van Zyl-Smit RN; Chapman KR; Kerstjens HAM; Gessner C; Sagara H; Tanase AM; Hosoe M; Pethe A; Lawrence D; Tillmann HC; D'Andrea P
J Asthma Allergy; 2023; 16():123-134. PubMed ID: 36714049
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies.
Sagara H; D'Andrea P; Tanase AM; Pethe A; Tanaka Y; Matsuo K; Hosoe M; Nakamura Y
J Asthma; 2023 Feb; 60(2):403-411. PubMed ID: 35348408
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers.
Vaidya S; Ziegler D; Tanase AM; Malmqvist U; Kanniess F; Hederer B; Hosoe M
Pulm Pharmacol Ther; 2021 Oct; 70():102019. PubMed ID: 33771722
[TBL] [Abstract][Full Text] [Related]
20. Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses.
van Zyl-Smit RN; Kerstjens HAM; Maspero J; Tanase AM; Lawrence D; Mezzi K; D'Andrea P; Chapman KR
Pulm Ther; 2023 Sep; 9(3):395-409. PubMed ID: 37526856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
